Biotechnology company BeiGene (NASDAQ:BGNE) (HKEX:06160) (SSE:688235) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673 for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have been previously treated with at least two prior lines of therapy.
BGB-16673 is an investigational Bruton's tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC).
The FDA's Fast Track Designation aims to expedite the development and review of drugs for serious conditions.
BGB-16673 has shown promising safety and efficacy in Phase 1/2 studies, offering a potential solution for patients with R/R CLL/SLL who have progressed on BTK inhibitors.
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA grants interchangeability status to SELARSDI from Alvotech and Teva
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
SKNV launches Kefunova Cream for actinic keratosis and superficial basal cell carcinoma
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF